Rothschild Raises AbbVie (ABBV) Price Target, Maintains Buy Rating

AbbVie Inc. (NYSE:ABBV) is one of the high-margin pharma stocks to buy now. AbbVie Inc. (NYSE:ABBV) received a slight boost in analyst sentiment this week as Rothschild & Co Redburn adjusted its price target on the stock to $240 from $239 while maintaining a Buy rating.

Rothschild Raises AbbVie (ABBV) Price Target, Maintains Buy Rating

A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist.

The revised target reflects continued confidence in AbbVie’s long-term outlook, bolstered by the company’s diversified portfolio and steady performance from its immunology and neuroscience divisions. While the change in target is modest, it underscores analysts’ expectations for gradual upside as AbbVie navigates the post-Humira landscape with its next-generation therapies, including Rinvoq and Skyrizi.

Rothschild & Co Redburn’s reiteration of its bullish stance suggests the firm sees limited downside risk, even as investors weigh headwinds such as pricing pressures and biosimilar competition. AbbVie shares have traded steadily over the past month, reflecting cautious optimism following solid earnings results and recent pipeline updates. The company is set to report next-quarter results later this month, which could offer further clarity on revenue trends and regulatory developments impacting its key assets.

While we acknowledge the risk and potential of ABBV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABBV and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Best Industrial Automation Stocks to Buy for the Next Decade

Disclosure: None. This article is originally published at Insider Monkey.